Prime Medicine (PRME) Revenue & Revenue Breakdown
Prime Medicine Revenue Highlights
0
Latest Revenue (Q)
$39.31M
Prime Medicine Revenue by Period
Prime Medicine Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $5.21M | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $5.21M | 100.00% |
| 2019-12-31 | - | - |
Prime Medicine generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Prime Medicine Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $39.31M | 6551.78% |
| 2024-03-31 | $591.00K | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Prime Medicine generated $39.31M in revenue during Q2 2024, up 6551.78% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Prime Medicine Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RPRX | Royalty Pharma | $2.35B | $564.69M |
| BEAM | Beam Therapeutics | $377.71M | $14.27M |
| CRSP | CRISPR Therapeutics | $370.00M | $602.00K |
| DNA | Ginkgo Bioworks | $251.46M | $89.05M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| NTLA | Intellia Therapeutics | $36.27M | $9.11M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| RLAY | Relay Therapeutics | $25.55M | - |
| VERV | Verve Therapeutics | $11.76M | $6.87M |
| IPSC | Century Therapeutics | $2.23M | $791.00K |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | $39.31M |
| SANA | Sana Bio | - | - |
| OCEA | Ocean Biomedical | - | - |